Innovent Biologics, Inc. · HKEX:1801

Innovent Biologics — FY2022 Earnings Presentation

32 slides from Innovent Biologics's earnings presentation, Mar 28, 2023

  1. Slide 1: Innovent Biologics 2022 Annual Results – Appendix Pipeline Overview

    Innovent Biologics 2022 Annual Results Appendix - Pipeline Overview March, 2023

  2. Slide 2: Robust Pipeline Across Novel Therapeutics – Oncology

    Robust Pipeline Across Novel Therapeutics – Oncology 7 approved, 2 NDAs, 3 in pivotal trials and over 10 assets in clinical stage Status Pivotal Phase 2 / Products Target (s) Modality Therapeutic Area Rights Pre-clinical IND Phase 1 Phase 1b/2 NDA Launched Phase 3 TYVYT® (sintilimab injection) PD-1

  3. Slide 3: Robust Pipeline Across Novel Therapeutics – Non-oncology

    Robust Pipeline Across Novel Therapeutics – Non-oncology 1 approved, 1 NDA, 2 in pivotal stage, 6 assets in clinical stage Pivotal Phase 2 / Products Target (s) Modality Therapeutic Area Rights Pre-clinical IND Phase 1 Phase 1b/2 NDA Launched Phase 3 SULINNO® (adalimumab) TNF-α Monoclonal antibody A

  4. Slide 4: Selected Pipeline - Oncology

    Selected Pipeline - Oncology

  5. Slide 5: TYVYT (Sintilimab): Only PD-1 Approved in NRDL for 1L of 5 Cancers

    TYVYT ®(Sintilimab): The Only PD-1 Inhibitor Approved and Included in NRDL for the First-line Treatment of 5 Major Types of Cancer 1L sqNSCLC 1L ESCC EGFRm nsqNSCLC 2021.06 sNDA Approval 2022.06 sNDA Approval 2021.12 sNDA Accepted 1L nsqNSCLC 1L HCC 1L GC 2021.02 sNDA Approval 2021.06 sNDA Approval

  6. Slide 6: Pemazyre (Pemigatinib, IBI375)

    Pemazyre® (Pemigatinib, IBI375) China first approved target therapy to fill the unmet medical need for cholangiocarcinoma Enzyme Inhibitory Activity of IBI375 Development Plan IBI375 • 2L mCCA (cholangiocarcinoma) - Approved in Taiwan market for 2L mCCA in 2021.06. Desired target activity - Approved

  7. Slide 7: Olverembatinib (BCR-ABL TKI, IBI348)

    Olverembatinib (BCR-ABL TKI, IBI348) China’s first approved and NRDL included third-generation BCR-ABL TKI Clinical Highlights Differentiated Advantages • IBI348 shown highly and durably efficacious in heavily TKI-pretreated • IBI348 is an oral third-generation BCR-ABL1 inhibitor designed for patien

  8. Slide 8: Cyramza (ramucirumab)

    Cyramza®(ramucirumab) A VEGFR2 antagonist approved for five indications of NSCLC, GC, HCC and CRC globally Clinical Highlights Development Plan GC: RAINBOW-Asia (ASCO GI 2021) HCC: Chinese population analysis in REACH-2 (2020 CSCO) • Entered into multifaceted collaboration with Eli Lilly in 2022.03

  9. Slide 9: Retsevmo (selpercatinib)

    Retsevmo® (selpercatinib) First-in-class selective RET inhibitor showing robust efficacy Clinical Highlights Differentiated Advantages Retsevmo ® global clinical trial data (LIBRETTO-001) • Retsevmo® is a highly selective and potent, CNS active RET inhibitor that exhibits unprecedented strong and du

  10. Slide 10: IBI326 (Equecabtagene Autoleucel, BCMA CAR-T)

    IBI326 (Equecabtagene Autoleucel, BCMA CAR-T) Fully-human and potentially first BCMA CAR-T approved in China Clinical Highlights (2022 EHA) Differentiated Advantage • Improved efficacy likely due to the lower binding affinity of BCMA CAR (facilitate serial triggering of CAR-T cell) and long-term per

  11. Slide 11: IBI376 (parsaclisib, PI3Kδ)

    IBI376 (parsaclisib, PI3Kδ) Potential Best-in-class PI3Kδ with NDA accepted and granted priority review IBI376 Demonstrated a High Rate of Rapid and Durable Response in r/r FL Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma

  12. Slide 12: IBI351 (KRAS G12C)

    IBI351 (KRASG12C) A potential Best-in-class KRASG12C selective inhibitor at pivotal Phase 2 IBI351 Potential in China First-Tier Development Status Development Program Overview ● Drug the historically ‘undruggable’ target • 2L KRASG12C muted NSCLC, CRC − KRAS G12C can be inhibited covalently ₋ Preli

  13. Slide 13: IBI344 (Taletrectinib, ROS1/TRK)

    IBI344 (Taletrectinib, ROS1/TRK) Leading next-generation ROS1/TRK at pivotal Phase 2 Clinical Highlights (2022 ASCO) Phase 2 Data (Data cutoff date: 2022.02.23) A: Crizotinib naive pts: ORR 92.5%(62/67)DCR 95.6% (64/67) B: Crizotinib pre-treated pts: ORR 50% (19/38) DCR 78.9% (30/38) C: Brain metast

  14. Slide 14: IBI126 (tusamitamab ravtansine)

    IBI126 (tusamitamab ravtansine) Global FIC and only Phase 3 stage ADC targeting CEACAM-5 Potential FIC ADC with humanized antibody of high selectivity for CEACAM5 • Potential FIC ADC with humanized antibody of high selectivity for CEACAM51 • — a cell-surface glycoprotein that is highly expressed on

  15. Slide 15: IBI939 (TIGIT): Encouraging Efficacy Signal in 1L NSCLC

    IBI939 (TIGIT) : Encouraging Efficacy Signal in 1L PD-L1 TPS>=50% NSCLC Trend of PFS improvement vs. PD-1 monotherapy Presentation #86P @ ESMO IMMUNO-ONCOLOGY CONGRESS 2022 STUDY DESIGN More PoC Ph1b data readout (eg. ASCO) PROGRESSION-FREE SURVIVAL CHANGES IN TARGET LESION SIZE FROM BASELINE IN ARM

  16. Slide 16: IBI110 (LAG3): Phase 1b Study for 1L sqNSCLC

    IBI110 (LAG3) : Phase 1b Study for 1L sqNSCLC PFS On-going Potentially improve the efficacy of sintilimab in the 1st line of major cancer indications Presentation #77P @ ESMO IMMUNO-ONCOLOGY CONGRESS 2022 STUDY DESIGN SWIMMING POOL OF OVERALL RESPONSE More PoC Ph1b data readout (eg. ASCO) SAFETY ANA

  17. Slide 17: IBI363 (PD-1/IL-2): Highly Potent Bispecific Fc Fusion Protein

    IBI363 (PD-1/IL-2) : Highly Potent Bispecific Fc Fusion Protein Mechanistically enhance IO treatment, including PD-1/PD-L1 resistant and cold tumors NOVEL MOLECULAR DESIGN STRATEGY CLINICAL PHASE 1 STUDY DESIGN ● IL-2Rɑ activity maintained for max efficacy & selectivity, while reduce ● Phase 1 ongoi

  18. Slide 18: IBI343: Potential Best-in-Class CLDN18.2 ADC

    IBI343: Potential Best-in-Class CLDN18.2 ADC Differentiated design for potential wide therapeutic window and high potency Differentiated Design Potential Best-in-Class Profiles • World leading ADC technology collaborated with Synaffix • Fully human, high internalization αCLDN18.2 mAb Asn297 • Silenc

  19. Slide 19: IBI343: Preclinical highlights & clinical progress

    IBI343: Potential Best-in-Class CLDN18.2 ADC Preclinical highlights & clinical progress Strong Bystander Killing Better In-vivo Efficacy than MMAE and Dxd Clinical Progress Heterogeneous TAA expression • Phase 1 MRCT ongoing in Australia and China since 2022, exploring in CLDN18.2+ solid cancers suc

  20. Slide 20: Selected Pipeline - Non-Oncology

    Selected Pipeline - Non-Oncology

  21. Slide 21: Tafolecimab (PCSK9, IBI306)

    Tafolecimab (PCSK9, IBI306) Potentially First Approved Domestic PCSK9 Data of Ph3 Studies (CREDIT-1 , CREDIT-2 and CREIDT-4) Percent change from baseline in 20 1.8%, placebo 600 mg Q6W LDL-C (%), LS mean (SE) 0 0.5%, placebo 450 mg Q4W −20 CREDIT-4 CREDIT-1 non-FH & non-FH −40 HeFH −55.6%, tafolecim

  22. Slide 22: Mazdutide (GLP-1R/GCGR, IBI362)

    Mazdutide (GLP-1R/GCGR, IBI362) Potentially the best GLP-1R/GCGR molecule to treat obesity and diabetes Balanced GLP-1R/GCGR Dual Agonist Development Program Overview ● 2022.06 Phase 2 study in obesity data readout ● 2022.07 Phase 2 study in T2DM data readout ● At ENDO 2022 data readout for Phase 1b

  23. Slide 23: Mazdutide: Robust weight loss effect in Phase 2 for obesity

    Mazdutide (GLP-1R/GCGR, IBI362) Proven robust weight loss effect in Phase 2 study for obesity 24-Week Weight Loss 11.6% at Dose Regime 2-4-6 mg 12-Week Weight Loss 11.7% at Dose Regime 3-6-9 mg Mean Body Weight Change at Week 24 The least squares (LS) mean percent change(absolute Overall mean baseli

  24. Slide 24: Mazdutide: Glycemic control and weight loss in Phase 2 diabetes

    Mazdutide (GLP-1R/GCGR, IBI362) Dual efficacy on glycemic control and weight loss in Phase 2 for diabetes 12 Week Proof Of Concept In Diabetes 20-Week Phase 2 Study In Diabetes IBI362 3.0 mg (n=43) HbA1c HbA1c 较基线的变化(%) reduction from baseline 100 Proportion of Participants IBI362 4.5 mg (n=43) FPG

  25. Slide 25: IBI128 (Tigulixostat)

    IBI128 (Tigulixostat) Potentially Best-in-class Phase 3 XOI for gout patients with hyperuricemia Role of Xanthine Oxidase in the Production of Uric Acid Clear Unmet Needs and BIC Profile • Huge population with gout/hyperuricemia (15M/177M) patients in China. Allopurinol / Febuxostat / IBI128 Tigulix

  26. Slide 26: IBI112 (IL-23p19): Potentially Best-in-class IL-23

    IBI112 (IL-23p19) : Potentially Best-in-class IL-23 Extended half-life, long-dosing interval and long-term efficacy Longest Dose Interval Compared with Launched Products • Bio engineer innovation: Fc YTE Mutation to prolong half life • 12weeks dosing interval: less dose frequency improved QOL signif

  27. Slide 27: IBI311 (IGF-1R)

    IBI311 (IGF-1R) Potentially Best-in-Class profile with clear unmet medical need in China Clear and Validated MoA Clear Unmet needs for active TAO • 170K new TAOs each year in China with no approved drug • Severely affects appearance and social functioning • No effective treatment to relieve proptosi

  28. Slide 28: IBI302 (efdamrofusp alfa): First-in-Class VEGF/Complement Fusion Protein

    IBI302 (efdamrofusp alfa) : First-in-Class VEGF/Complement Fusion Protein Potential effect in anti-macular atrophy and longer durability Ph2 primary endpoint met: BCVA gains with IBI302 Q8W Less macular atrophy on OCT in IBI302 group at week 36 & were noninferior to 2mg Aflibercept Q8W at week 36 &

  29. Slide 29: IBI353 (Orismilast)

    IBI353 (Orismilast) Potentially Best-in-class Phase 2 PDE4 inhibitor Clinical Highlights Development Program Overview Indirect comparison Psoriasis from Ph2a suggests Orismilast oral ● In 2022.11, Innovent have successfully Share of Psoriasis potential to be ~50% dosed the first Chinese healthy volu

  30. Slide 30: VEGF Cluster: IBI333 & IBI324

    VEGF Cluster: IBI333 (VEGF-A/VEGF-C) & IBI324 (VEGF-A/ANG-2) A bispecific recombinant fully humanized A bispecific antibody targeting VEGF- IBI333 fusion protein targeting VEGF-A and VEGF-C IBI324 A and Ang2 Free VEGF A VEGFR domain2 ✱ Anti-VEGF-A scFv Inhibit neovascularization Inhibit vascular lea

  31. Slide 31: From Molecule to Blockbuster

    From Molecule to Blockbuster: Robust pipeline to address unmet medical needs with huge global market potential Innovent focus on therapeutic area with unmet medical needs and large market potential Inno focused TAs Others 377 Oncology Next-generation IO: LAG3, TIGIT, PD-L1/IL2… ADC : CLDN18.2, B7H3,

  32. Slide 32: Confidential

    Confidential Copyright© 2023 Innovent 32

Innovent Biologics — FY2022 Earnings Presentation on 6ix